GSK3B and Alzheimer disease: It is worth noting that GSK-3β activity was demonstrated to regulate PPARγ activity [95], and the two PPARγ agonists, PIO, and rosiglitazone have been reported to enhance hippocampal Akt/GSK3β phosphorylation in animal models of AD [57, 96].